@online{u.s._food_and_drug_administration_guidance_nodate,
	title = {Guidance for Industry Non-Inferiority Clinical Trials},
	url = {http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf},
	abstract = {Excerpt: "This guidance provides sponsors and review staff in the Center for Drug Evaluation and Research ({CDER}) and Center for Biologic Evaluation and Research ({CBER}) at the Food and Drug Administration ({FDA}) with our interpretation of the underlying principles involved in the use of non-inferiority ({NI}) study designs to provide evidence of the effectiveness of a drug or biologic. The guidance gives advice on when {NI} studies can be interpretable, on how to choose the {NI} margin, and how to analyze the results."},
	author = {U.S. Food \{and\} Drug Administration},
	urldate = {2011-11-16}
}

